To Evaluate the Safety and PK Characteristics After Co-ad... | NCT06754943

Status Module

Oversight Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Group 1	Other	Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 Treatment B: Administration alone of 1 tablet of JW0105	Drug: Treatment A_Period 1 Drug: Treatment B_Period 2 Drug: Treatment A_Period 3 Drug: Treatment B_Period 4
Group 2	Other	Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 Treatment B: Administration alone of 1 tablet of JW0105	Drug: Treatment B_Period 1 Drug: Treatment A_Period 2 Drug: Treatment B_Period 3 Drug: Treatment A_Period 4

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Treatment A_Period 1	Drug	Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 Wash-out period: 21 days Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
AUCt	Plasma concentrations are measured using a validated LC-MS/MS.	Day 1 (0 hour) ~ Day 3 (72 hour) post-dose in period 1, period 2, period 3, and period 4
Cmax	Plasma concentrations are measured using a validated LC-MS/MS.	Day 1 (0 hour) ~ Day 3 (72 hour) post-dose in period 1, period 2, period 3, and period 4

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Sung-Dae Kwon	Metro Hospital	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Metro Hospital		Anyang-si	Gyeonni-do	14096	South Korea

IPD Sharing Statement Module

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

No data available

No data is available for this block.

Intervention Browse Module